| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6487288 | Current Opinion in Biotechnology | 2018 | 7 Pages |
Abstract
Clinical trials of cell-based therapies that use pluripotent stem cells (PSC) have already started for several neurological diseases including spinal cord injury and age-related macular degeneration. Regarding future PSC-based clinical trials for other neurological diseases, these trials have been instrumental at recognizing first, the difference between research cell lines and clinical cell lines of a stem cell product, second, the selection of an appropriate animal model for pre-clinical study, third, criteria and the quality control of donor cells, and fourth, the mode of action of the grafts.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Jun Takahashi,